How long should an Andarine S4 cycle typically last for research purposes?

An Andarine S4 cycle most commonly runs six to eight weeks. Eight weeks is the benchmark duration cited across the majority of SARM research protocols, balancing measurable outcomes against the suppression risk that accumulates with prolonged administration. Cycles shorter than six weeks rarely allow full expression of the compound's tissue-selective effects, while cycles beyond twelve weeks carry disproportionate hormonal recovery costs.

What dose range is standard when starting an Andarine S4 protocol?

The standard entry dose is 25 mg per day for the first week, which corresponds to one Master Pharma tablet. Most protocols then advance to 50 mg daily in weeks two and three. Experienced researchers may escalate to 75 mg daily for weeks four through eight. Starting low lets the user observe individual response before committing to higher daily totals.

How long should the break be after completing an Andarine S4 cycle?

The established guideline is an off-period equal in length to the cycle itself — so an eight-week cycle requires at least eight weeks before the next run. This window allows LH and FSH levels to normalise, a process that SARM pharmacokinetic literature places at four to eight weeks depending on cumulative dose and personal physiology.

Why does the 25mg per tablet concentration matter for cycle dosing accuracy?

At 25 mg per tablet, each dose increment — 25 mg, 50 mg, 75 mg — corresponds to exactly one, two, or three whole tablets. This eliminates the need to split or approximate doses, reducing variability across a multi-week protocol. Batch Tested HPLC verification on every Master Pharma production lot confirms that the 25 mg label value reflects actual content, which is critical when dosing precision drives protocol outcomes.

How should Master Pharma Andarine tablets be stored to maintain potency across a full 60-tablet cycle?

Tablets should be stored in a cool, dry location away from direct light and humidity — a sealed container at room temperature between 15 °C and 25 °C is adequate. Unlike liquid SARM preparations, solid oral tablets are not subject to degradation from repeated opening, making the 60-tablet blister or bottle format straightforward to manage across an eight-week cycle without special handling. (2) angle_used

Batch Tested

Master Pharma

Andarine (S4) 25mg/tab 60 Tablets by Master Pharma

Name: Andarine (S4)
Brand: Master Pharma
SKU: SARM-ANDA-MAS-003
Price: 65.00 EUR
Availability: InStock

Andarine (S4) is a selective androgen receptor modulator supplied by Master Pharma as 25 mg tablets — a concentration calibrated for structured cycle planning where precise per-tablet dosing makes weekly escalation and de-escalation straightforward. Each 60-tablet pack covers a full research cycle from entry dose through peak and taper phases without a mid-cycle reorder. Quality assurance is built on lot-specific HPLC purity verification and LAL endotoxin testing; every batch ships with a Certificate of Analysis confirming both results.

€65.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers precise 25 mg increments that map directly onto published dose-escalation schedules
60-tablet count covers a complete eight-week cycle at 50 mg/day without reordering
Batch Tested via HPLC and LAL assay — every lot confirmed before release
Short six-to-eight-hour half-life permits rapid mid-cycle dose adjustments
Selective androgen receptor binding limits off-target androgenic activity compared to exogenous androgens
Lot-specific Certificate of Analysis issued per production batch for full traceability
Solid oral tablet format eliminates degradation concerns associated with liquid formulations

Phase	Daily Dose	Note
Entry (Week 1)	25 mg (1 tablet)	Baseline tolerance assessment; observe response before escalating
Build (Weeks 2–3)	50 mg (2 tablets)	Standard research dose; distribute across morning and early evening
Peak (Weeks 4–8)	50–75 mg (2–3 tablets)	75 mg reserved for experienced users; monitor vision sensitivity
Taper (Final 5–7 days)	25 mg (1 tablet)	Gradual reduction to support endogenous hormone recovery onset
Time-Off	0 mg	Minimum eight weeks; PCT support initiated from final tablet

Key takeaways

Follow an eight-week maximum cycle before scheduling a full recovery break.
Escalate from 25 mg to 50 mg in week two to manage tolerance progressively.
Plan time-off equal to cycle length for complete hormonal normalisation.
Verify every batch with the included Batch Tested Certificate of Analysis.
Use whole-tablet increments to maintain precise dosing throughout the protocol.

What Andarine (S4) Is and How Protocol Planning Shapes Its Use

Andarine (S4) is a non-steroidal SARM that binds selectively to skeletal-muscle and bone androgen receptors, making structured cycle and dose planning the primary determinant of outcome and tolerability. Master Pharma's 25 mg tablet format supports that planning by delivering a consistent, measurable unit that maps directly onto published dose-escalation schedules. The compound carries an approximate half-life of six to eight hours, confirmed across pharmacokinetic studies, which informs how total daily intake is distributed across waking hours.

Dose Ranges and Cycle Length: What Research Data Shows

Research protocols typically begin Andarine at 25 mg per day during the first week — one tablet — before advancing to 50 mg per day in weeks two and three, and optionally to 75 mg per day for experienced users in weeks four through eight. Compared to longer-acting SARMs such as LGD-4033, Andarine's shorter half-life allows dose adjustments to take effect and wash out faster, giving researchers greater flexibility when modifying protocols mid-cycle. An eight-week cycle is the most commonly documented duration; exceeding twelve weeks increases suppression risk without proportionate benefit according to available literature. Master Pharma's 60-tablet pack at 25 mg per tablet provides exactly the tablet count required to complete a full eight-week cycle at 50 mg/day with no surplus waste.

Time-Off Planning and Hormonal Recovery

Time-off planning follows the standard equal-time rule: an eight-week cycle warrants a minimum eight-week recovery window before the next run. Andarine (S4) suppresses endogenous testosterone production in a dose-dependent manner; LH and FSH recovery timelines measured in clinical SARM research typically range from four to eight weeks post-cycle, depending on cumulative dose and individual response. A post-cycle support protocol is therefore recommended from the final tablet onward. Master Pharma's batch-tested manufacturing — HPLC identity and potency verified, LAL endotoxin-quantified, lot-specific COA issued — ensures the dose recorded on the label is the dose delivered, which is a non-negotiable requirement when following a time-sensitive, numerically precise protocol.

Usage

Calculate your full cycle tablet requirement before starting — an eight-week cycle at 50 mg/day requires 280 tablets; a 25 mg/day entry week adds seven, for a total of 287 tablets across nine weeks.
Begin at 25 mg (one tablet) on Day 1 and hold that dose for the entire first week to establish a baseline response.
Advance to 50 mg daily from Day 8 onward, distributing the dose across two administrations timed to the compound's six-to-eight-hour half-life.
Record daily observations — energy, recovery, any visual disturbance — in a cycle log so that dose decisions in weeks four through eight are data-driven rather than subjective.
Do not extend the active cycle beyond twelve weeks regardless of perceived tolerance; suppression accumulates non-linearly at prolonged durations.
Begin time-off planning before the final week: schedule PCT support, note the calendar date for the earliest permissible next cycle start, and retain the batch COA for reference throughout recovery.

Warnings

Contraindications: Not indicated for individuals under 21, those with pre-existing androgen-sensitive conditions, or anyone currently using exogenous hormone therapies. Women of childbearing potential should not use this compound.

Side Effects: Dose-dependent testosterone suppression is the primary hormonal risk; vision sensitivity changes — distinct from permanent impairment — have been documented at doses above 50 mg/day and resolve upon dose reduction or cessation. Elevated liver enzyme values have been reported in extended-duration protocols.

Monitoring: Baseline and end-of-cycle bloodwork covering LH, FSH, total testosterone, and liver function panels (ALT, AST) is recommended. Vision should be self-assessed daily; any persistent changes warrant immediate dose reduction.

PCT: A post-cycle support protocol should begin on the day after the final tablet. A four-to-six-week PCT window is standard following an eight-week Andarine cycle at 50 mg/day; consult a qualified healthcare professional regarding agent selection and duration.

Frequently asked questions

How long should an Andarine S4 cycle typically last for research purposes?: An Andarine S4 cycle most commonly runs six to eight weeks. Eight weeks is the benchmark duration cited across the majority of SARM research protocols, balancing measurable outcomes against the suppression risk that accumulates with prolonged administration. Cycles shorter than six weeks rarely allow full expression of the compound's tissue-selective effects, while cycles beyond twelve weeks carry disproportionate hormonal recovery costs.
What dose range is standard when starting an Andarine S4 protocol?: The standard entry dose is 25 mg per day for the first week, which corresponds to one Master Pharma tablet. Most protocols then advance to 50 mg daily in weeks two and three. Experienced researchers may escalate to 75 mg daily for weeks four through eight. Starting low lets the user observe individual response before committing to higher daily totals.
How long should the break be after completing an Andarine S4 cycle?: The established guideline is an off-period equal in length to the cycle itself — so an eight-week cycle requires at least eight weeks before the next run. This window allows LH and FSH levels to normalise, a process that SARM pharmacokinetic literature places at four to eight weeks depending on cumulative dose and personal physiology.
Why does the 25mg per tablet concentration matter for cycle dosing accuracy?: At 25 mg per tablet, each dose increment — 25 mg, 50 mg, 75 mg — corresponds to exactly one, two, or three whole tablets. This eliminates the need to split or approximate doses, reducing variability across a multi-week protocol. Batch Tested HPLC verification on every Master Pharma production lot confirms that the 25 mg label value reflects actual content, which is critical when dosing precision drives protocol outcomes.
How should Master Pharma Andarine tablets be stored to maintain potency across a full 60-tablet cycle?: Tablets should be stored in a cool, dry location away from direct light and humidity — a sealed container at room temperature between 15 °C and 25 °C is adequate. Unlike liquid SARM preparations, solid oral tablets are not subject to degradation from repeated opening, making the 60-tablet blister or bottle format straightforward to manage across an eight-week cycle without special handling. (2) angle_used

Manufacturer

Master Pharma's distribution infrastructure for oral tablet SKUs is structured around regional cold-chain partnerships that maintain package integrity from production release through last-mile delivery — a logistical requirement that oral SARMs share with temperature-sensitive peptide formats despite different stability profiles. For the Andarine 25 mg tablet line, each dispatched lot is accompanied by its lot-specific Certificate of Analysis: HPLC active-content result and LAL endotoxin figure are locked to the production batch number printed on the packaging, allowing the receiving party to cross-reference shipment documentation against the analytical record at point of receipt. Customs classification, import documentation, and carrier selection are managed at the distributor level to meet the regulatory requirements of each destination market, with Master Pharma supplying the batch-level paperwork required for in-country compliance review.

Product details

Brand	Master Pharma
Active ingredient	andarine
Also known as	S-4, Andarine (S4), Master Pharma S-4
Strength	25 mg
Form	Tabletten
Pack size	60 pieces
Item number	SARM-ANDA-MAS-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Andarine 10mg/tab 60 Tablets by Elbrus Pharmaceuticals

Lab Tested

Andarine 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Andarine (S-4) is a non-steroidal SARM developed to selectively activate androgen receptors in skeletal muscle and bone, making it a primary choice for athletes seeking simultaneous fat loss, muscle hardness, and enhanced vascularity during a caloric deficit. Each 10 mg tablet provides exact, repeatable dosing — removing the measurement variability common with liquid S-4 formats and enabling clean titration across a split-dose schedule. Potency and purity are confirmed at the finished-tablet level: every production batch passes HPLC concentration analysis and LAL endotoxin testing, with both outcomes recorded against a lot number before distribution begins.

€70.00

Pharma Grade

Andarine 25mg/tab 30 Tablets by Vital Research

Andarine (S-4) by Vital Research is a selective androgen receptor modulator supplied in 25 mg tablets, engineered to serve as a versatile anchor compound across both cutting and bulking SARM stacks. At 25 mg per tablet — the highest concentration in this product group — precise dose management becomes straightforward whether you are pairing with Ostarine and Cardarine for a lean-out phase or with LGD-4033 and RAD-140 for a mass-building cycle. Every batch undergoes independent HPLC purity verification and LAL endotoxin testing; GMP-compliant production standards govern each manufacturing run.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00